English  |  正體中文  |  简体中文  |  Items with full text/Total items : 16564/18988 (87%)
Visitors : 5432564      Online Users : 64
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cnu.edu.tw/handle/310902800/28545


    標題: DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model
    作者: Weng, T-Y
    Yen, M-C
    Huang, C-T
    Hung, J-J
    Chen, Y-L
    Chen, W-C
    Wang, C-Y
    Chang, J-Y
    Lai, M-D
    貢獻者: 老人服務事業管理系
    關鍵字: GROWTH-FACTOR RECEPTOR
    K-RAS MUTATIONS
    IMMUNE-RESPONSE
    GENE GUN
    IN-VIVO
    PROGNOSTIC-SIGNIFICANCE
    INTERFERON-GAMMA
    DOWN-REGULATION
    T-LYMPHOCYTES
    TUMOR-CELLS
    日期: 2014-10
    上傳時間: 2015-05-06 21:20:08 (UTC+8)
    出版者: Nature Publishing Group
    摘要: Mutant Kras (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) is observed in more than 20% of non-small-cell lung cancers; however, no effective Kras target therapy is available at present. The Kras DNA vaccine may represent as a novel immunotherapeutic agent in lung cancer. In this study, we investigated the antitumor efficacy of the Kras DNA vaccine in a genetically engineered inducible mouse lung tumor model driven by Kras(G12D). Lung tumors were induced by doxycycline, and the therapeutic effects of Kras DNA vaccine were evaluated with delivery of Kras(G12D) plasmids. Mutant Kras(G12D) DNA vaccine significantly decreased the tumor nodules. A dominant-negative mutant Kras(G12D)N17, devoid of oncogenic activity, achieved similar therapeutic effects. The T-helper 1 immune response was enhanced in mice treated with Kras DNA vaccine. Splenocytes from mice receiving Kras DNA vaccine presented an antigen-specific response by treatment with peptides of Kras but not Hras or OVA. The number of tumor-infiltrating CD8(+) T cells increased after Kras vaccination. In contrast, Kras DNA vaccine was not effective in the lung tumor in transgenic mice, which was induced by mutant L858R epidermal growth factor receptor. Overall, these results indicate that Kras DNA vaccine produces an effective antitumor response in transgenic mice, and may be useful in treating lung cancer-carrying Ras mutation.
    關聯: Gene therapy, v.21 n.10, pp.888-896
    Appears in Collections:[老人服務事業管理系] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML430View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback